Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Chiasma, Inc.    CHMA

CHIASMA, INC.

(CHMA)
  Report
Delayed Quote. Delayed Nasdaq - 03/01 04:00:00 pm
3.95 USD   +1.54%
02/25Chiasma to Report Fourth Quarter 2020 Results on March 4
GL
01/19CHIASMA  : Overview
PU
01/19CHIASMA  : Hires John Doyle as CFO
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Chiasma : Hires John Doyle as CFO

01/19/2021 | 07:37am EST


© MT Newswires 2021
All news about CHIASMA, INC.
02/25Chiasma to Report Fourth Quarter 2020 Results on March 4
GL
01/19CHIASMA  : Overview
PU
01/19CHIASMA  : Hires John Doyle as CFO
MT
01/19CHIASMA, INC  : Change in Directors or Principal Officers, Financial Statements ..
AQ
01/19Chiasma Announces Hiring of John Doyle as Chief Financial Officer
GL
01/06CHIASMA  : Overview
PU
01/06CHIASMA, INC  : Results of Operations and Financial Condition, Regulation FD Dis..
AQ
01/06Chiasma Provides Corporate Update and Previews Expected 2021 Milestones
GL
2020INSIDER TRENDS : 90-Day Buying Trend Extended with Insider Purchase of Chiasma S..
MT
2020INSIDER TRENDS : Chiasma Sees 90 Days of Insider Selling, Trend Scaled Back with..
MT
More news
Financials (USD)
Sales 2020 1,24 M - -
Net income 2020 -76,7 M - -
Net Debt 2020 - - -
P/E ratio 2020 -2,66x
Yield 2020 -
Capitalization 228 M 228 M -
Capi. / Sales 2020 184x
Capi. / Sales 2021 8,47x
Nbr of Employees 85
Free-Float 99,3%
Chart CHIASMA, INC.
Duration : Period :
Chiasma, Inc. Technical Analysis Chart | CHMA | US16706W1027 | MarketScreener
Technical analysis trends CHIASMA, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Average target price 13,20 $
Last Close Price 3,95 $
Spread / Highest target 356%
Spread / Average Target 234%
Spread / Lowest Target 153%
EPS Revisions
Managers and Directors
NameTitle
Raj Kannan President, Chief Executive Officer & Director
John Doyle Chief Financial Officer, Treasurer & Senior VP
David M. Stack Chairman
William Ludlam Senior VP-Clinical Development & Medical Affairs
David Plante Vice President-Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
CHIASMA, INC.-10.57%225
CSL LIMITED-4.56%92 178
WUXI BIOLOGICS (CAYMAN) INC.-0.49%52 131
SAMSUNG BIOLOGICS CO.,LTD.-9.20%43 986
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.25.76%43 127
BIOGEN INC.11.44%41 569